{"title":"代谢综合征患者颈动脉内膜厚度与成纤维细胞生长因子结合蛋白-3 之间的关系","authors":"Goncagul Akdag, Esma Güldal Altunoğlu","doi":"10.4274/imj.galenos.2023.19626","DOIUrl":null,"url":null,"abstract":"group (p=0.049). Conclusion: In our study, there was no relationship between serum FGFBP-3 levels and CIMT. However, there was a relationship between FGFBP-3 and high SBP and diabetes. We believe that FGFBP-3 can stabilize the bioactivity of endogenous FGF21 and therefore may have significant therapeutic benefits in metabolic diseases such as non-alcoholic fatty liver disease and type 2 DM.","PeriodicalId":42584,"journal":{"name":"Istanbul Medical Journal","volume":"24 4","pages":""},"PeriodicalIF":0.2000,"publicationDate":"2023-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Relationship between Carotid Intima-Media Thickness and Fibroblast Growth Factor Binding Protein-3 in Patients with Metabolic Syndrome\",\"authors\":\"Goncagul Akdag, Esma Güldal Altunoğlu\",\"doi\":\"10.4274/imj.galenos.2023.19626\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"group (p=0.049). Conclusion: In our study, there was no relationship between serum FGFBP-3 levels and CIMT. However, there was a relationship between FGFBP-3 and high SBP and diabetes. We believe that FGFBP-3 can stabilize the bioactivity of endogenous FGF21 and therefore may have significant therapeutic benefits in metabolic diseases such as non-alcoholic fatty liver disease and type 2 DM.\",\"PeriodicalId\":42584,\"journal\":{\"name\":\"Istanbul Medical Journal\",\"volume\":\"24 4\",\"pages\":\"\"},\"PeriodicalIF\":0.2000,\"publicationDate\":\"2023-11-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Istanbul Medical Journal\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4274/imj.galenos.2023.19626\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Istanbul Medical Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4274/imj.galenos.2023.19626","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
Relationship between Carotid Intima-Media Thickness and Fibroblast Growth Factor Binding Protein-3 in Patients with Metabolic Syndrome
group (p=0.049). Conclusion: In our study, there was no relationship between serum FGFBP-3 levels and CIMT. However, there was a relationship between FGFBP-3 and high SBP and diabetes. We believe that FGFBP-3 can stabilize the bioactivity of endogenous FGF21 and therefore may have significant therapeutic benefits in metabolic diseases such as non-alcoholic fatty liver disease and type 2 DM.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
